Navigation Links
CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
Date:9/10/2012

KING OF PRUSSIA, Pa., Sept. 10, 2012 /PRNewswire/ -- CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

Under the terms of the contract, the U.S. Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The Company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.

"We are very pleased to again be working with the U.S. Government on its pandemic preparedness efforts," said Dr. John Anderson, Senior Vice President of CSL Biotherapies.  "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."

Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract No HHSO100201200011I.  The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract.

About CSL Biotherapies

The United States headquarters of CSL Biotherapies are located in King of Prussia, PA. Its parent company, CSL Limited, in Melbourne, Australia (ASX: CSL) has invested  US$ 80million to double the Company's influenza manufacturing capacity to 40 million trivalent influenza vaccine doses per season, making it one of the largest influenza vaccine facilities for global markets. CSL Biotherapies, which shares its United States headquarters with its sister company, CSL Behring, commercializes influenza vaccine products globally. The CSL Group employs more than 11,000 people and operates in 27 countries worldwide. For more information, visit us at www.csl.com.au and at http://www.cslbiotherapies-us.com.

Media Contact:  
Sheila Burke
Director, Commercial Operations Communications and Public Relations
610-878-4209


'/>"/>
SOURCE CSL Biotherapies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. K computer research results awarded ACM Gordon Bell Prize
2. BioPower Systems Awarded $5 Million from Victorian Government
3. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
4. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
5. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
6. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
7. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
8. Sloan Research Fellowships Awarded to 126 Young Scholars
9. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
10. Chemring Detection Systems Awarded $500k for Strategic Research and Development
11. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... and WASHINGTON, DC, USA (PRWEB) , ... May 23, 2017 , ... ... of the economy as well as an enabler of life-saving medical and other vital ... optics and photonics . They joined others in the scientific community today in responding ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... human cardiovascular cells for research and the development of cardiac regeneration therapies. ... generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... advanced technology applications, has announced a facility expansion to accommodate its rapid growth. ... feet of new workspace and renovation of the existing areas. The expansion includes, ...
(Date:5/22/2017)... ... 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare companies ... opened an office in downtown Boston at 745 Atlantic Ave. , “We are ... generate evidence on the value they provide, not just to patients, but also payers. ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
Breaking Biology News(10 mins):